67 reports of this reaction
1.3% of all AMPICILLIN SODIUM AND SULBACTAM SODIUM reports
#14 most reported adverse reaction
RESPIRATORY FAILURE is the #14 most commonly reported adverse reaction for AMPICILLIN SODIUM AND SULBACTAM SODIUM, manufactured by Roerig. There are 67 FDA adverse event reports linking AMPICILLIN SODIUM AND SULBACTAM SODIUM to RESPIRATORY FAILURE. This represents approximately 1.3% of all 4,969 adverse event reports for this drug.
Patients taking AMPICILLIN SODIUM AND SULBACTAM SODIUM who experience respiratory failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY FAILURE is a less commonly reported adverse event for AMPICILLIN SODIUM AND SULBACTAM SODIUM, but still significant enough to appear in the safety profile.
In addition to respiratory failure, the following adverse reactions have been reported for AMPICILLIN SODIUM AND SULBACTAM SODIUM:
The following drugs have also been linked to respiratory failure in FDA adverse event reports:
RESPIRATORY FAILURE has been reported as an adverse event in 67 FDA reports for AMPICILLIN SODIUM AND SULBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY FAILURE accounts for approximately 1.3% of all adverse event reports for AMPICILLIN SODIUM AND SULBACTAM SODIUM, making it a notable side effect.
If you experience respiratory failure while taking AMPICILLIN SODIUM AND SULBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.